NPB001-05 Inhibits BCR-Abl Kinase Leading to Apoptosis of Imatinib-Resistant Cells

Frontiers in Bioscience - Elite - United States
doi 10.2741/e331
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers in Bioscience

Related search

MPT0B169, a New Antitubulin Agent, Inhibits BCR-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells

PLoS ONE
Multidisciplinary
2016English

Anti-Rheumatic Agent Auranofin Induced Apoptosis in Chronic Myeloid Leukemia Cells Resistant to Imatinib Through Both BCR/Abl-Dependent and -Independent Mechanisms

Oncotarget
Oncology
2014English

Nilotinib Significantly Induces Apoptosis in Imatinib Resistant K562 Cells With Wild-Type BCR–ABL, as Effectively as in Parental Sensitive Counterparts

Hematology
Hematology
2010English

Simultaneous Targeting of Aurora Kinases and BCR-Abl Kinase by the Small Molecule Inhibitor PHA-739358 Is Effective Against Imatinib-Resistant BCR-ABL Mutations Including T315I

Blood
BiochemistryImmunologyCell BiologyHematology
2008English

BCR-ABL Tyrosine Kinase

Science-Business eXchange
2012English

Targeting the SH2-Kinase Interface in BCR-Abl Inhibits Leukemogenesis

Cell
BiochemistryGeneticsMolecular Biology
2011English

In Vitro and in Vivo Activity of SKI-606, a Novel SRC-Abl Inhibitor, Against Imatinib-Resistant BCR-Abl+ Neoplastic Cells

Cancer Research
Cancer ResearchOncology
2006English

Protein Kinase CKIIa Interacts With the BCR Moiety of BCR/Abl and Mediates Proliferation of BCR/Abl-Expressing Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2004English

Detection of Single Nucleotide Insertion of BCR/ABL Region in Imatinib-Resistant Human Myelogenous Leukemia SR-1 Cells

Experimental & Molecular Medicine
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy